A team of research scientists at the University of Freiburg (Albert-Ludwigs-Universität Freiburg) at Freiburg im Breisgau, Baden-Württemberg, Germany, the University of Geneva, and the University of Grenoble report that they have succeeded in preventing the hospital-acquired bacteria Pseudomonas aeruginosa, a pathogen particularly dangerous to persons with Cystic Fibrosis (CF), from…
News
The nonprofit organization Claire’s Place Foundation, founded by a 17-year-old cystic fibrosis patient (CF), was recently awarded “Small Nonprofit Organization of the Year” by the Los Angeles Business Journal. The recognition was attributed to the positive the impact that the organization named after Claire Wineland has had on children and…
The first Princeton, IL cystic fibrosis (CF) walk raised over $13,000 recently, $3,000 more than expected. The Great Strides Cystic Fibrosis Walk, held on June 28th, was organized by 28-year-old student Cheriz Kunkel, who was diagnosed with CF when she was a baby. Kunkel announced that the walk was a major…
Baby Bridget, born on June 27th, became the first baby conceived in Ireland using pre-implantation genetic diagnosis (PGD), a technique used to screen embryos for genetic mutations such as cystic fibrosis (CF). Despite the fact that both parents have genetics that, when combined, can lead to CF in their children, baby…
Vertex Submits FDA Supplemental New Drug Application for Kalydeco in People with R117H CF Mutation
In the wake of recent promising clinical results, Vertex Therapeutics announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration for the approval of the drug Kalydeco (ivacaftor) for patients with cystic fibrosis who are more than 18 years old and…
Hemolung Respiratory Assist System (RAS) is an innovative Pittsburgh-made, dialysis-like alternative or supplement to mechanical ventilation that is not approved by the U.S. Food and Drug Administration (FDA), but is gaining several positive opinions in the United States, following the promising results when used on an American terminal patient suffering from…
Drug developer Pharmaxis has announced that the company’s medication for cystic fibrosis, Bronchitol, was included in the shortlist for the UK Prix Galien Orphan Drug Award, an internationally-recognized prize that distinguishes technical, scientific, and clinical research skills necessary to develop innovative medicines. The therapies in the competition will be analyzed…
PTC Therapeutics Initiates Second Phase 3 Trial of Ataluren in Nonsense Mutation Cystic Fibrosis
In an effort to alleviate symptoms in patients with nonsense mutation cystic fibrosis–a severe form that leads to little if any CFTR protein production–PTC Therapeutics, Inc. is initiating a global confirmatory Phase 3 clinical trial to test Translarna (ataluren) under the trial name ACT CF. In a previous,…
What happens when a cystic fibrosis charity and a biotechnology company team up through a partnership? The answer is a Phase IIa clinical trial in the United Kingdom put together by Cystic Fibrosis Trust and NovaBiotics. Also included in the effort are the University of Aberdeen, Health Science Scotland,…
In the wake of positive news about new combination therapies involving the Vertex drug Kalydeco (ivacaftor) for people with cystic fibrosis (CF), the drug recently received a positive recommendation for approval by the European Committee for Medicinal Products for Human Use (CHMP) for patients aged…
Your CF Community

Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.
Recent Posts
- Learning to advocate for ourselves in healthcare settings
- Cystic fibrosis signs in newborns may not predict poorer long-term outcomes
- When cystic fibrosis interrupts the joy of life
- ‘Voicemails for Isabelle’ creator wins award for spotlighting CF
- Navigating seasonal changes and infection control following transplant